170291-46-0

Upstream product

• 95299-16-4 methyl [3,5-bis(trifluoromethyl)-phenyl]-acetate 
• 158144-85-5 1-t-butoxycarbonyl-4-phenyl-4-hydroxymethyl piperidine 
• 170291-48-2 methyl α-diazo-3,5-bis(trifluoromethyl)benzeneacetate 

Downstream Products

• 170291-50-6 N-{2-[(N-tert-butoxycarbonyl-4-phenylpiperidin-4-yl)methoxy]-2-(3,5-bis(trifluoromethyl)phenyl)acetyl}-4(R)-benzyl-2-oxazolidinone 
• 1025823-00-0 4-[(3,5-bis-trifluoromethyl-phenyl)-chlorocarbonyl-methoxymethyl]-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester 
• 170291-49-3 2-(1-tert-Butoxycarbonyl-4-phenylpiperidine-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetic acid 

Relevant academic research and scientific papers

1-AMIDO-4-PHENYL-4-BENZYLOXYMETHYL-PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROKININ-1(NK-1) ANTAGONISTS FOR THE TREATMENT OF EMESIS, DEPRESSION, ANXIETY AND COUGH

Disclosed are NK1 antagonists having the formula: Also disclosed are uses of compounds of formula (I) for the manufacture of a medicament for treating a number of physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Gem-disubstituted azacyclic tachykinin antagonists

The present invention is directed to certain compounds represented by structural formula I: STR1 or a pharmaceutically acceptable salt thereof wherein R 1, R 2, R 3, R 4, R 5, R 6, R 7, A 1, A 2, X, m and n are defined herein. The compounds of this invention are tachykinin receptor antagonists and are of particular use in the treatment of pain, inflammation, migraine and emesis.